1-2 of 2
Chan C. Whiting
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Open Access
Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1100–1110.
https://doi.org/10.1158/2767-9764.CRC-24-0082
Published: 18 April 2024
View articletitled, First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Open the PDF for First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors

Open Access
Brian J. Francica, Anja Holtz, Justine Lopez, David Freund, Austin Chen, Dingzhi Wang, David Powell, Franciele Kipper, Dipak Panigrahy, Raymond N. Dubois, Chan C. Whiting, Peppi Prasit, Thomas W. Dubensky
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1486–1500.
https://doi.org/10.1158/2767-9764.CRC-23-0249
Published: 08 August 2023
View articletitled, Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Open the PDF for Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors in another window
Includes: Supplementary data